Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: A retrospective study

BMC Anesthesiology

Volumn 13, Issue , 2013, Pages

  Doshi, Neha M ^a   Cook, Charles H ^b   Mount, Kari L ^b   Stawicki, Stanislaw P ^b   Frazee, Erin N ^c   Personett, Heather A ^c   Schramm, Garrett E ^c   Arnold, Heather M ^d   Murphy, Claire V ^b  

^a ST LUKE S UNIVERSITY HEALTH NETWORK   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

^d BARNES JEWISH HOSPITAL   (United States)

Author keywords

Acinetobacter; Aerosolized; Colistin; Critical illness; Multiple drug resistance; Pneumonia; Pseudomonas

Indexed keywords

COLISTIN;

ACINETOBACTER BAUMANNII; ADULT; AEROSOL; ARTICLE; ARTIFICIAL VENTILATION; COHORT ANALYSIS; CRITICALLY ILL PATIENT; DRUG EFFICACY; FEMALE; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTI DRUG RESISTANT GRAM NEGATIVE PNEUMONIA; MULTICENTER STUDY; PNEUMONIA; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY;

EID: 84888125167     PISSN: None     EISSN: 14712253     Source Type: Journal    
DOI: 10.1186/1471-2253-13-45     Document Type: Article

References (21)

1. Michalopoulos A, Kasiakou SK, Mastora Z, et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Crit Care 2005, 9:R53-R59. 10.1186/cc3020, 1065114, 15693967.
2. Laessig KA. End points in hospital-acquired pneumonia and/or ventilator-associated pneumonia in clinical trials: food and drug administration perspective. Clin Inf Dis 2010, 51:S117-S119.
3. Jones ME, Draghi DC, Thornsberry C, et al. Emerging resistance among bacterial pathogens in the intensive care unit-a European and North American surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004, 3:14. 10.1186/1476-0711-3-14, 509280, 15283864.
4. Li J, Nationa RL, Turnidge JD, et al. Colistin: The re-emerging antibiotic for multi-drug resistant gram-negative bacterial infections. Lancet Infect Dis 2006, 6:589-601. 10.1016/S1473-3099(06)70580-1, 16931410.
5. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother 1999, 33:960-967. 10.1345/aph.18426, 10492501.
6. Lu Q, Girardi C, Zhang M, et al. Nebulized and intravenous colistin in experimental pneumonia caused by pseudomonas aeruginosa. Int Care Med 2010, 36:1147-1155.
7. Kofteridis DP, Alexopoulou C, Valachis A, et al. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis 2010, 51:1238-1244. 10.1086/657242, 20973727.
8. Korbila IP, Michalopoulos A, Rafailidis PI, et al. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect 2010, 16:1230-1236.
9. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health-care associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008, 36:309-322. 10.1016/j.ajic.2008.03.002, 18538699.
10. Le F, Ashley ED, Neuhauser MM, et al. Consensus summary of aerosolized antimicrobial agents: application of guideline criteria: insights from the society of infectious diseases pharmacists. Pharmacotherapy 2010, 30:562-584. 10.1592/phco.30.6.562, 20500046.
11. Michalopoulos A, Papadakis E. Inhaled anti-infective agents: emphasis on colistin. Infection 2010, 38:81-88. 10.1007/s15010-009-9148-6, 20191398.
12. Kwa ALH, Loh C, Low JGH, et al. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Inf Dis 2005, 41:754-757.
13. Lin CC, Liu TC, Kuo CF, et al. Aerosolized colistin for the treatment of multi-drug resistant Acinetobacter baumannii pneumonia: experience in a tertiary care hospital in northern Taiwan. J Microbiol Immunol Infect 2010, 43:323-331. 10.1016/S1684-1182(10)60050-3, 20688293.
14. Falagas ME, Siempos II, Rafailidis PI, et al. Inhaled colistin as monotherapy for multidrug-resistant gram(-) nosocomial pneumonia: a case series. Resp Med 2009, 103:707-713.
15. Fagon JY, Chastre J, Domart Y, et al. Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis 1996, 23:538-542. 10.1093/clinids/23.3.538, 8879777.
16. Visscher S, Schruink CA, Melsen WG, et al. Effects of systemic antibiotic therapy on bacterial persistence in the respiratory tract of mechanically ventilated patients. Int Care Med 2008, 34:692-699.
17. Vakil N. Acid inhibition and infections outside the gastrointestinal tract. Am J Gastroenterol 2009, 104:S16-S20.
18. Dennesen PJW, van de Ven JAM, Kessels AGH, Ramsay G, Bonten MJM. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001, 163:1371-1375. 10.1164/ajrccm.163.6.2007020, 11371403.
19. Petrosillo N, Ioannidou E, Falagas ME. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin Microbiol Infect 2008, 14:216-227.
20. Rynn C, Wootton M, Bowker KE, et al. In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics. Clin Microbiol Infect 1999, 5:32-36.
21. Timurkaynak F, Can F, Azap OK, et al. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006, 27:224-228. 10.1016/j.ijantimicag.2005.10.012, 16464562.